

CORRECTION

Correction: The KRAS-G12C inhibitor: activity and resistance

Jiao Liu, Rui Kang and Daolin Tang

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023

Cancer Gene Therapy (2023) 30:1715; <https://doi.org/10.1038/s41417-023-00692-1>

Correction to: *Cancer Gene Therapy* (2021) 29:875–878
<https://doi.org/10.1038/s41417-021-00383-9>,
published online 01 September 2021

in the 3rd paragraph, 6th sentence of the Introduction, “Compared with the wild-type, the KRAS mutation disrupts the guanine exchange cycle, thereby locking it in an inactive GDP-bound form that drives pro-tumorigenic signals [18] (Fig. 1b).”

Should be changed to:

“Compared with the wild-type, the KRAS mutation disrupts the guanine exchange cycle, thereby locking it in an active GTP-bound form that drives pro-tumorigenic signals [18] (Fig. 1b).”

The original article has been corrected.